NASDAQ:PGEN Precigen Q1 2025 Earnings Report $7.44 -0.45 (-5.70%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$7.46 +0.02 (+0.28%) As of 04:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Precigen EPS ResultsActual EPS-$0.07Consensus EPS -$0.08Beat/MissBeat by +$0.01One Year Ago EPSN/APrecigen Revenue ResultsActual Revenue$1.34 millionExpected Revenue$0.50 millionBeat/MissBeat by +$840.00 thousandYoY Revenue GrowthN/APrecigen Announcement DetailsQuarterQ1 2025Date5/14/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time4:00PM ETUpcoming EarningsPrecigen's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Precigen Earnings HeadlinesPrecigen (NASDAQ:PGEN) Hits New 12-Month High - What's Next?September 23 at 5:12 AM | americanbankingnews.comPrecigen, Inc. (NASDAQ:PGEN) Receives Average Rating of "Moderate Buy" from BrokeragesSeptember 23 at 4:28 AM | americanbankingnews.comElon gets it. Do you?Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news. Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point. | Porter & Company (Ad)Precigen's AdenoVerse Receives FDA Platform Technology DesignationSeptember 22 at 8:00 AM | finance.yahoo.comPrecigen Receives FDA Platform Technology Designation for AdenoVerse PlatformSeptember 21 at 7:00 AM | prnewswire.comPrecigen (PGEN) Stock May Be Fully Valued On Its Current Sales BaseSeptember 18, 2026 | finance.yahoo.comSee More Precigen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Precigen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precigen and other key companies, straight to your email. Email Address About PrecigenPrecigen (NASDAQ:PGEN) (NASDAQ:PGEN) is a biotechnology company focused on developing gene and cell therapies for cancer and other serious diseases. The company uses its synthetic biology platforms to engineer targeted medicines designed to improve treatment effectiveness, durability and safety. Precigen’s technology portfolio includes its UltraCAR-T platform for developing next-generation CAR-T cell therapies, the AdenoVerse platform for gene delivery and immunotherapy applications, and ActoBiotics technology for the localized delivery of therapeutic proteins. Its pipeline has included programs in oncology, autoimmune disease and infectious disease. One of the company’s leading programs is PRGN-2012, an investigational immunotherapy developed for recurrent respiratory papillomatosis, a rare disease caused by human papillomavirus. Precigen conducts research and clinical development through collaborations and operations serving patients and healthcare markets in the United States and internationally.View Precigen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
